8 October 2024

Dear SMA Europe,

In response to your request, we are pleased to share a summary of the results from Part B and C of the Phase 2/3 DEVOTE study, which are being presented at the World Muscle Society (WMS) 2024 Congress this week in Prague.

Summary of DEVOTE Results Presented at WMS: *Higher dose regimen of nusinersen shows benefits in both individuals previously treated and treatment-naïve to nusinersen with infantile-onset and later-onset SMA*

DEVOTE is a three-part study that enrolled 145 participants across all ages and SMA types. The study evaluated the safety and efficacy of an investigational higher dose regimen of nusinersen, which comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen of 28 mg every four months. Study analyses compared the higher dose regimen to either a matched, untreated control group from the ENDEAR study or the currently available 12 mg regimen.

DEVOTE: Part B

In Part B, 75 treatment-naïve infants with symptomatic infantile-onset SMA received either the investigational higher dose regimen of nusinersen or the 12 mg regimen.

- Part B met the primary endpoint showing symptomatic infants who received the higher dose regimen saw a significantly greater 15.1-point improvement in motor function as measured by CHOP-INTEND compared to a decline of 11.1 points for the untreated control group.
- Secondary analyses consistently favored the higher dose regimen in all comparisons to the control group and in nearly all comparisons to the 12 mg regimen.

DEVOTE: Part C

In Part C, a diverse group of 40 participants, age 4-65 years, transitioned from the 12 mg regimen after a median of 3.9 years on treatment to one 50 mg dose followed by the 28 mg maintenance regimen. Initial results presented at WMS show:

- Following the transition, participants experienced improvements in motor function with mean increases of 1.8 points on Hammersmith Functional Motor Scale-Expanded (HFMSE) and 1.2 points on Revised Upper Limb Module (RULM) from baseline at Day 302.

Overall, the higher dose regimen was generally well tolerated and showed a safety profile similar to that of the currently available 12 mg regimen.

Biogen plans to submit regulatory applications around the world for approval of the nusinersen higher dose regimen (50/28 mg).

Biogen is committed to supporting people living with SMA by advancing research that aims to address unmet need for the community. We are deeply appreciative of the patients, caregivers, and investigators who have participated in the DEVOTE study and thank the SMA community for your efforts to support those living with the condition. We are happy to answer any questions you

may have regarding the DEVOTE study and are available to provide updates in the future upon request.

Kind Regards,
Cindy

Cindy McGee Manieri
Head of Corporate Affairs Rare Disease, International
Biogen International GmbH

Prepared in October 2024

Biogen-250381